Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Submit a comment

Translational Control of Hemoglobin Synthesis in Thalassemic Bone Marrow
Gabriel Cividalli, … , David G. Nathan, Harvey F. Lodish
Gabriel Cividalli, … , David G. Nathan, Harvey F. Lodish
Published April 1, 1974
Citation Information: J Clin Invest. 1974;53(4):955-963. https://doi.org/10.1172/JCI107661.
View: Text | PDF
Research Article

Translational Control of Hemoglobin Synthesis in Thalassemic Bone Marrow

  • Text
  • PDF
Abstract

Previous studies of β-thalassemic reticulocytes have implied a decreased amount of functional β-mRNA but unimpaired translation of the β-mRNA present. However, the β/α synthetic ratios in β-thalassemic marrow are higher than those observed in reticulocytes of the same patients. This could imply that marrow cells contain an abnormally functioning β-mRNA no longer active in reticulocytes. To test the function of mRNA found in marrow, intact cells were incubated with [35S]methionine and the relative amounts of nascent α- and β-chains on polysomes of different sizes were measured by tryptic digestion and determination of the specific activities of the respective peptides. Results showed that in normal and β-thalassemic marrow, as well as in reticulocytes, β-chain production, though deficient, occurs predominantly on larger polysomes than the production of α-chains. In one patient with severe thalassemia and very little production of β-chains in marrow or reticulocytes, δ-chain synthesis was found predominantly on larger polysomes than α-chain synthesis. These results indicate that in β-thalassemic as well as in nonthalassemic marrow and reticulocytes, each β- and δ-mRNA initiates protein synthesis at a rate faster than does each α-mRNA, and suggest that the β-mRNA in contact with polyribosomes is normally functioning but quantitatively deficient in β-thalassemic marrow as well as in reticulocytes. No translational defect was detected in a similar study performed in reticulocytes of a patient with hemoglobin H disease, suggesting a normally functioning mRNA in contact with polyribosomes in this condition as well. In both thalassemias, unbalanced synthesis of α- and β-chains was more pronounced on polysomes than in completed chains. This difference possibly reflects a compensatory delay in translation of the nonthalassemic chain, which is present in excess.

Authors

Gabriel Cividalli, David G. Nathan, Harvey F. Lodish

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts